AMICUS THERAPEUTICS
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.
AMICUS THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2002-01-01
Address:
Cranbury, New Jersey, United States
Country:
United States
Website Url:
http://www.amicusrx.com
Total Employee:
501+
Status:
Active
Contact:
(609)662-200
Total Funding:
843.05 M USD
Technology used in webpage:
LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Domain Not Resolving Euro Amazon IPv6 JsDelivr
Similar Organizations
Agile Therapeutics
Agile Therapeutics is pharmaceutical company developing contraceptive healthcare products for women.
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Koya Medical
Koya Medical is a transformative healthcare company developing breakthrough treatments for lymphedema and venous diseases.
Munogenics
Munogenics is dedicated to developing therapies for the treatment of a wide variety of cancers in both humans and animals.
IVERIC bio
IVERIC bio is a biopharmaceutical company developing novel therapies for age-related macular degeneration.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Sorriso Pharmaceuticals
Sorriso Pharmaceuticals is a biotech firm developing disease-modifying antibodies for the treatment of inflammatory diseases.
Vigeo Therapeutics
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors.
Current Advisors List
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
John Crowley Executive Chairman @ Amicus Therapeutics
Executive Chairman
2005-01-01
Jayne Gershkowitz Chief Patient Advocate @ Amicus Therapeutics
Chief Patient Advocate
2016-05-01
Bradley L. Campbell President & Chief Executive Officer @ Amicus Therapeutics
President & Chief Executive Officer
2006-01-01
Jayne Gershkowitz Senior Vice President & Chief Patient Advocate @ Amicus Therapeutics
Senior Vice President & Chief Patient Advocate
2015-05-01
Hung Do Chief Science Officer @ Amicus Therapeutics
Chief Science Officer
2015-06-01
David Clark Chief People Officer @ Amicus Therapeutics
Chief People Officer
2018-10-01
Jay Barth Chief Medical Officer @ Amicus Therapeutics
Chief Medical Officer
2014-03-01
Alex Fell Head Ethics, Compliance and DPO International @ Amicus Therapeutics
Head Ethics, Compliance and DPO International
2020-07-01
Jayne Gershkowitz Vice President, Patient Advocacy & Public Policy @ Amicus Therapeutics
Vice President, Patient Advocacy & Public Policy
2013-01-01
Enrique Diloné Vice President @ Amicus Therapeutics
Vice President
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2018-09-20 | Celenex | Celenex acquired by Amicus Therapeutics | 452 M USD |
| 2015-08-31 | Scioderm | Scioderm acquired by Amicus Therapeutics | 847 M USD |
| 2013-11-01 | Callidus Biopharma | Callidus Biopharma acquired by Amicus Therapeutics | N/A |
Investors List
Hayfin Capital Management
Hayfin Capital Management investment in Post-IPO Debt - Amicus Therapeutics
Silicon Valley Bank
Silicon Valley Bank investment in Post-IPO Debt - Amicus Therapeutics
Oxford Finance LLC
Oxford Finance LLC investment in Post-IPO Debt - Amicus Therapeutics
MidCap Financial
MidCap Financial investment in Post-IPO Debt - Amicus Therapeutics
GlaxoSmithKline
GlaxoSmithKline investment in Post-IPO Equity - Amicus Therapeutics
Muscular Dystrophy Association
Muscular Dystrophy Association investment in Grant - Amicus Therapeutics
Michael J. Fox Foundation
Michael J. Fox Foundation investment in Grant - Amicus Therapeutics
Prospect Venture Partners
Prospect Venture Partners investment in Series D - Amicus Therapeutics
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series D - Amicus Therapeutics
CHL Medical Partners
CHL Medical Partners investment in Series D - Amicus Therapeutics
Official Site Inspections
http://www.amicusrx.com Semrush global rank: 936.1 K Semrush visits lastest month: 38.33 K
- Host name: amicus-ws1.embercloud.io
- IP address: 44.196.157.127
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Amicus Therapeutics"
Amicus Therapeutics | Advancing Therapies to Treat Rare Diseases
Amicus Therapeutics) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering high-quality medicines for people living with rare …See details»
Who We Are | AmicusRX Therapeutics
The How. We take pride in the talented individuals that make up our organization and work hard to foster their growth. Each and every one of us plays a role in building the culture that supports our Mission, creates the Innovation we need, …See details»
Amicus Therapeutics - Wikipedia
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. [3] The company went public in 2007 under the NASDAQ trading symbol …See details»
Corporate Responsibility - Amicus Therapeutics
Amicus is of course no exception – we are deeply committed to performance with integrity. Important sources of our strong commitment are the tone and direction from our CEO and Board, as well as the unusually strong bond and friendship …See details»
Amicus Therapeutics - LinkedIn
Amicus Therapeutics | 46,632 followers on LinkedIn. Our passion for making a difference unites us. | We are a global, patient-dedicated biotechnology company focused on discovering, developing ...See details»
Belief Statement | AmicusRX Therapeutics
We seek to deliver the highest quality therapies for persons living with these diseases; We support the disease communities – and their familiesSee details»
Amicus Therapeutics - Crunchbase Company Profile
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called …See details»
Amicus Therapeutics, Inc. FORM 10-K SECURITIES AND …
Incorporation or Organization) Identification Number) 47 Hulfish Street, Princeton, NJ 08542 (Address of Principal Executive Offices) (Zip Code) (609) 662-2000 (Registrant's Telephone …See details»
Wer wir sind | AmicusRX Therapeutics
Unser Warum. Wir sind ein SELTENES Unternehmen voller begeisterter und leidenschaftlicher Unternehmerinnen und Unternehmer mit dem Ziel, die Besten in der Rare-Disease-Community zu sein.See details»
Amicus Therapeutics | American Nephrology Nurses Association
3675 Market Street Philadelphia, PA 19104 215-921-7600 Fax 215-921-7900 info@amicusrx.com www.amicusrx.com. Amicus Therapeutics is a global, patient-dedicated biotechnology …See details»
Amicus Therapeutics Information - RocketReach
Additional international office locations include Australia, Canada, France, Japan, Germany, Italy, The Netherlands, and Spain. More information about Amicus and our career opportunities can …See details»
AMICUS THERAPEUTICS, INC. CORPORATE GOVERNANCE …
AMICUS THERAPEUTICS, INC. CORPORATE GOVERNANCE GUIDELINES The board of directors (the “Board”) of Amicus Therapeutics, Inc. (the “Company”) has developed corporate …See details»
Working At Amicus Therapeutics: Company Overview and Culture
Mar 14, 2024 www.amicusrx.com. Organization Type. Public. CEO. John Francis Crowley. Social Media. Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the …See details»
Dimerix and Amicus Therapeutics Announce Exclusive License
2 days ago afaughnan@amicusrx.com +1 (609) 662-3809. Media: Amicus Therapeutics Diana Moore Head of Global Corporate Affairs and Communications dmoore@amicusrx.com +1 …See details»
Amicus Careers Who We Are - Amicus Therapeutics
The How. We take pride in the talented individuals that make up our organization and work hard to foster their growth. Each and every one of us plays a role in building the culture that …See details»
Ethics and Compliance | Amicus Therapeutics
Patient Organization Support. Patients and the advocacy organizations that represent them are at the heart of everything we do. It is the mothers, fathers, sons, and daughters – the real people …See details»
Amicus Therapeutics Announces First Quarter 2025 Financial …
1 day ago Amicus Therapeutics, Inc. 1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER. Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for …See details»
Amicus Therapeutics (USA) Funding: $2.4B - medicalstartups.org
Apr 24, 2025 Amicus Therapeutics is a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare and orphan...See details»
Global Medical Affairs Program | Amicus Therapeutics
If your organization is interested in receiving Amicus RFEs, please send us an email at GMA_IME@amicusrx.com. Grant Submission Process. Submit an application through our …See details»
Amicus Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...
CONTACT: Investors: Amicus Therapeutics Andrew FaughnanVice President, Investor Relationsafaughnan@amicusrx.com(609) 662-3809 Media: Amicus Therapeutics Diana Moore …See details»